Ceremony to commemorate recent FDA clearance milestone for Company’s Evo® sEEG Electrode technology
EDEN PRAIRIE, Minn., Nov. 22, 2022 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will ring the Nasdaq closing bell today Tuesday, November 22, 2022, to commemorate its recent corporate milestone achievement for the Evo® thin film electrode platform.
The NeuroOne closing bell ceremony will be broadcast live starting at 3:50 p.m. Eastern Time from Nasdaq MarketSite in New York City’s Times Square. The live broadcast may be viewed on Livestream and Facebook. Following an introduction by Nasdaq, NeuroOne CEO Dave Rosa will deliver brief remarks and then ring the bell at 4:00 p.m. alongside other members of the NeuroOne team.
Dave Rosa commented, “Last month we received FDA 510(k) clearance to market our Evo sEEG Electrode technology for temporary (less than 30 days) use with equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. This was our Company’s most exciting achievement to date, rounding out the full functionality of our Evo sEEG System* and advancing our manufacturing ramp and commercialization efforts for this advanced line of diagnostic electrodes. We are excited to celebrate this victory at Nasdaq’s iconic bell ringing ceremony.”
*Caution: Federal law restricts this device to sale by or on the order of a physician.
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit www.n1mtc.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding our manufacturing ramp and commercialization activities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether due to supply chain disruptions, labor shortages, the impact of COVID-19 or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that the COVID-19 pandemic will continue to adversely impact our business; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-ring-nasdaq-stock-market-closing-bell-on-november-22-301683578.html
SOURCE NeuroOne Medical Technologies Corporation
ABC Action News tracks tropical developments in the Atlantic and Gulf of Mexico.
Top 10 Goalie Saves of the Week, 11/20/2022
These two high-quality tech companies have seen their stocks trampled in the gutters of Wall Street this year. Nevertheless, they are poised for a soaring comeback in the long haul.
Yahoo Finance’s Jared Blikre breaks down the latest moves in the stock and bond markets as Fed officials comment on the path of rate hikes.
In this article, we talk about 10 stocks that billionaire Ray Dalio dumped from his portfolio. If you want to see more stocks in this selection, check out Billionaire Ray Dalio is Dumping These 5 Stocks. Ray Dalio is an American billionaire hedge fund manager, philanthropist, and the founder of Bridgewater Associates, one of the […]
FTX collapsed. These players held the keys.
Trouble had been brewing for months as CFO Christine McCarthy and other senior figures campaigned with the Disney board to force Chapek out.
Two stocks I would steer clear of today include Tilray Brands (NASDAQ: TLRY) and DoorDash (NYSE: DASH). Next year will be a crucial one for cannabis producer Tilray Brands. Tilray has been busy with acquisitions and will likely pursue more over the next 12 months.
Three top ones that investors will probably eventually regret not buying at their current prices are Enbridge (NYSE: ENB), Enterprise Products Partners (NYSE: EPD), and Energy Transfer (NYSE: ET). Enbridge's dividend currently clocks in at a 6.4% yield. With its stock price recently around $40 a share, it trades at about 10 times cash flow.
Recently, Zacks.com users have been paying close attention to ZIM (ZIM). This makes it worthwhile to examine what the stock has in store.
Dycom Industries (DY) delivered earnings and revenue surprises of 32.03% and 7.01%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
It has been a challenging year for investors, but we can all take heart in the fact that some of the world's most renowned investors are finding opportunities in the bear market and are initiating positions in new stocks. Warren Buffett is arguably the most renowned investor of all time, so anytime his Berkshire Hathaway initiates a new position, it makes a splash within the investment community. Buffett has said that it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.
It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 30% drop has been the most acute, while the S&P 500 now sits 17% lower year-to-date. That said, while it’s hard to watch any owned stock sink to the bottom, the upside to the downside is that investors
These supercharged income stocks, with yields ranging from 8.5% to 17.7%, were on billionaire money manager's buy lists during the third quarter.
GE (GE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
For anyone looking to get ahead in the investing game, following in the footsteps of stock picking legends is an obvious path to follow. Hardly any are more legendary than George Soros, forever known as the ‘man who broke the Bank of England,’ after pocketing a cool billion dollars in one day when betting against the Pound back in 1992. That single act, however, does not define Soros, who has made sound investment decisions throughout his career which bought decades-long returns of 30% to his Qu
Shares of Brazilian oil company Petroleo Brasileiro (NYSE: PBR) (NYSE: PBR.A) slipped somewhat this morning after investment bank UBS flipped 180 degrees from buy to sell on the oil stock. The amount of the decline is in some dispute, with Google Finance clocking an 18% fall on PBR shares from a closing price of $11.40 per share last night, while Yahoo! Finance says it closed at only $10.10 per share and is down only 4%.
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.
Medtronic reported mixed earnings and lighter-than-expected organic sales growth, leading MDT stock to tumble.
Canadian Solar (CSIQ) delivered earnings and revenue surprises of 93.10% and 5.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ceremony to commemorate recent FDA clearance milestone for Company’s Evo® sEEG Electrode technology